Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Tumor-associated macrophages (TAMs) can be educated within the tumor microenvironment to promote cancer development and progression. While TAM-targeted agents have largely focused on macrophage depletion as an anticancer strategy, it is becoming increasingly evident that TAM re-education may represent a more effective approach. In this perspective, we discuss different means to achieve TAM re-education, and review the beneficial effects of these strategies, particularly when combined with immune checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Self-citationMacrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Self-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Zhang, Q.-W., Liu, L., Gong, C.-Y., Shi, H.-S., Zeng, Y.-H., Wang, X.-Z., Zhao, Y.-W., & Wei, Y.-Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050946 · Cited by 1,039
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738
Biswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., Rasmussen, R., Dwivedi, B., Seby, S., Wolf, S. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2310 · Cited by 675
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Self-citationCessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
Müller, S., Kohanbash, G., Liu, S. J., Alvarado, B., Carrera, D., Bhaduri, A., Watchmaker, P. B., Yagnik, G., Di Lullo, E., Malatesta, M., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1362-4 · Cited by 654
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies
Bowman, R. L., Klemm, F., Akkari, L., Pyonteck, S. M., Sevenich, L., Quail, D. F., Dhara, S., Simpson, K., Gardner, E. E., Iacobuzio-Donahue, C. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.052 · Cited by 619
Self-citationHarney, A. S., Arwert, E. N., Entenberg, D., Wang, Y., Guo, P., Qian, B.-Z., Oktay, M. H., Pollard, J. W., Jones, J. G., & Condeelis, J. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0012 · Cited by 618
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1
Hussain, S. F., Yang, D., Suki, D., Aldape, K., Grimm, E., & Heimberger, A. B. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-008 · Cited by 592
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Self-citationMolecular control of activation and priming in macrophages
Glass, C. K., & Natoli, G. (2016) · Nature Immunology · doi:10.1038/ni.3306 · Cited by 530
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
Karagiannis, G. S., Pastoriza, J. M., Wang, Y., Harney, A. S., Entenberg, D., Pignatelli, J., Sharma, V. P., Xue, E. A., Cheng, E., D’Alfonso, T. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0026 · Cited by 497
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Genard, G., Lucas, S., & Michiels, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00828 · Cited by 419
Liposomes for Specific Depletion of Macrophages from Organs and Tissues
van Rooijen, N., & Hendrikx, E. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60327-360-2_13 · Cited by 379
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Pucci, F., Venneri, M. A., Biziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., Naldini, L., & De Palma, M. (2009) · Blood · doi:10.1182/blood-2009-01-200931 · Cited by 328
Macrophages of distinct origins contribute to tumor development in the lung
Loyher, P.-L., Hamon, P., Laviron, M., Meghraoui-Kheddar, A., Goncalves, E., Deng, Z., Torstensson, S., Bercovici, N., Baudesson de Chanville, C., Combadière, B., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180534 · Cited by 298
Long, K. B., Gladney, W. L., Tooker, G. M., Graham, K., Fraietta, J. A., & Beatty, G. L. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1032 · Cited by 275
Baer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M. (2016) · Nature Cell Biology · doi:10.1038/ncb3371 · Cited by 259
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 236
Self-citationHigh-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors
Ojalvo, L. S., King, W., Cox, D., & Pollard, J. W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080676 · Cited by 221
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 219
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Moskalenko, M., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 197
Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.018 · Cited by 180
Cuccarese, M. F., Dubach, J. M., Pfirschke, C., Engblom, C., Garris, C., Miller, M. A., Pittet, M. J., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms14293 · Cited by 168
Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
Perry, C. J., Muñoz-Rojas, A. R., Meeth, K. M., Kellman, L. N., Amezquita, R. A., Thakral, D., Du, V. Y., Wang, J. X., Damsky, W., Kuhlmann, A. L., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171435 · Cited by 165
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Beatty, G. L., Li, Y., & Long, K. B. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 163
Wiehagen, K. R., Girgis, N. M., Yamada, D. H., Smith, A. A., Chan, S. R., Grewal, I. S., Quigley, M., & Verona, R. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0258 · Cited by 162
Harney, A. S., Karagiannis, G. S., Pignatelli, J., Smith, B. D., Kadioglu, E., Wise, S. C., Hood, M. M., Kaufman, M. D., Leary, C. B., Lu, W.-P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0241 · Cited by 161
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents
Olson, O. C., Kim, H., Quail, D. F., Foley, E. A., & Joyce, J. A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.038 · Cited by 143
Self-citationCSF-1R Inhibitor Development: Current Clinical Status
Peyraud, F., Cousin, S., & Italiano, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0634-1 · Cited by 116
Therapeutic Targeting of Tumor-associated Macrophages and Microglia in Glioblastoma
Bowman, R. L., & Joyce, J. A. (2014) · Immunotherapy · doi:10.2217/imt.14.48 · Cited by 45
Self-citationCSF1R-dependent myeloid cells are required for NK‑mediated control of metastasis
Beffinger, M., de Lara, P. T., Tugues, S., Vermeer, M., Montagnolo, Y., Ohs, I., Cecconi, V., Lucchiari, G., Gagliardi, A., Misljencevic, N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97792 · Cited by 45
A drug development perspective on targeting tumor‐associated myeloid cells
Majety, M., Runza, V., Lehmann, C. H. K., Hoves, S., & Ries, C. H. (2017) · FEBS Journal · doi:10.1111/febs.14277 · Cited by 38
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM reeducation, and TAM depletion [88, 96, 101, 102] .”
BackgroundMethodTherapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Self-citationKlemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J.-P., Iacobuzio-Donahue, C. A., Brennan, C., Tabar, V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,037
Self-citationRedefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment
Wu, K., Lin, K., Li, X., Yuan, X., Xu, P., Ni, P., & Xu, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01731 · Cited by 687
Macrophages at the interface of the co-evolving cancer ecosystem
Kloosterman, D. J., & Akkari, L. (2023) · Cell · doi:10.1016/j.cell.2023.02.020 · Cited by 427
Metadata
- Authors
- Kowal, J., Kornete, M., & Joyce, J. A.
- Affiliations
- Ludwig Cancer Research (CH)
- Corresponding author
- Joyce, Johanna A
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2019-05-15
- Volume
- 11
- Issue
- 8
- Pages
- 677-689
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2945653463
- Cited by
- 161
- References
- 66
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 12 · 2023: 26 · 2022: 32 · 2021: 39 · 2020: 19 · 2019: 6
- FWCI
- 9.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Immunotherapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by-nc-nd)
- IRIS (submittedVersion, cc-by-nc-nd)
- Funders
- Swiss Cancer League
- Swiss Bridge Award
- Breast Cancer Research Foundation
- Cancer Research UK, Ludwig Institute for Cancer Research, and the University of Lausanne
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, tumor microenvironment, TAM-targeted therapy, macrophage depletion, immune checkpoint inhibitors, cancer immunotherapy, tumor progression
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.